Kazia Therapeutics Limited announced on November 2, 2026 that two abstracts on paxalisib's preclinical and translational research have been accepted for poster presentation at the San Antonio Breast Cancer Symposium, scheduled for December 8 through 11, 2026, in San Antonio, Texas.

Key Highlights

  • Two posters accepted: Kazia received acceptance for two abstracts at the 2026 San Antonio Breast Cancer Symposium (SABCS), taking place December 8 through 11, 2026.
  • Poster 1 (P4-9-18): Addresses paxalisib's "durable tumour and immune reprogramming across breast cancer subtypes" and challenges the assumption that dual PI3K/mTOR inhibitors are biologically equivalent, according to the filing.
  • Poster 2 (P4-10-26): Examines suppression of local and metastatic recurrence via adjuvant PI3K/mTOR inhibition following neoadjuvant chemo-immunotherapy in a preclinical model of stage III triple-negative breast cancer (TNBC).
  • Differentiated mechanism: The company stated the research "suggests that these effects are not necessarily shared by other dual PI3K/mTOR inhibitors" and that the mechanism "extends beyond conventional kinase inhibition."
  • Paxalisib designations: According to the filing, paxalisib holds U.S. FDA Fast Track and Orphan Drug designations for glioblastoma, Fast Track designation for PI3K-altered brain metastases with radiation, and Rare Pediatric Disease and Orphan Drug designations for select pediatric brain tumors.

Paxalisib Breast Cancer Research to Be Presented at SABCS December 2026

Kazia Therapeutics Limited (NASDAQ:KZIA) disclosed on November 2, 2026 that two research abstracts focused on paxalisib have been accepted for poster presentation at this year's San Antonio Breast Cancer Symposium. The conference is scheduled to take place December 8 through 11, 2026, in San Antonio, Texas, according to the announcement.

The first poster, designated P4-9-18, is titled "Paxalisib uniquely induces durable tumour and immune reprogramming across breast cancer subtypes, challenging the paradigm that dual PI3K/mTOR inhibitors are biologically equivalent." The second poster, P4-10-26, is titled "Suppression of Local and Metastatic Recurrence by Adjuvant PI3K/mTOR Inhibition Through Durable Immune Epigenetic Rewiring Following Neoadjuvant Chemo-Immunotherapy in Stage III Triple-Negative Breast Cancer." Both titles are reproduced verbatim as stated in the filing.

The company described paxalisib as "an investigational oral, brain-penetrant dual PI3K/mTOR inhibitor being developed across multiple forms of cancer, including cancers of the central nervous system, advanced breast cancer and colorectal cancer." The filing also noted that Kazia is advancing two additional preclinical programs: NDL2, described as a nuclear PD-L1 protein degrader, and MSETC, described as a SETDB1 inhibitor. The company's portfolio also includes EVT801, a small molecule VEGFR-3 inhibitor, which Kazia stated it is "exploring for potential partnering opportunities." The filing contains forward-looking statements, which the company noted are subject to risks including the possibility that "results of preclinical and translational studies may not be predictive of results in clinical trials in humans."

What Was Disclosed

Kazia Therapeutics announced acceptance of two paxalisib research posters at the 2026 SABCS conference. The abstracts cover preclinical tumor and immune reprogramming comparisons and a TNBC recurrence suppression study, both set for presentation December 8 through 11, 2026.